The promise of biological markers for treatment response in first-episode psychosis: a systematic review

Schizophrenia Bulletin
Guillaume FondMarion Leboyer

Abstract

Successful treatment of first-episode psychosis is one of the major factors that impacts long-term prognosis. Currently, there are no satisfactory biological markers (biomarkers) to predict which patients with a first-episode psychosis will respond to which treatment. In addition, a non-negligible rate of patients does not respond to any treatment or may develop side effects that affect adherence to the treatments as well as negatively impact physical health. Thus, there clearly is a pressing need for defining biomarkers that may be helpful to predict response to treatment and sensitivity to side effects in first-episode psychosis. The present systematic review provides (1) trials that assessed biological markers associated with antipsychotic response or side effects in first-episode psychosis and (2) potential biomarkers associated with biological disturbances that may guide the choice of conventional treatments or the prescription of innovative treatments. Trials including first-episode psychoses are few in number. Most of the available data focused on pharmacogenetics markers with so far only preliminary results. To date, these studies yielded-beside markers for metabolism of antipsychotics-no or only a few biomarkers for re...Continue Reading

References

Jan 1, 1983·Pharmacology & Therapeutics·B StruppP W Gold
Jan 1, 1994·Psychoneuroendocrinology·R D Oades, R Schepker
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·V G KimonidesJ Herbert
Apr 16, 1998·The British Journal of Psychiatry : the Journal of Mental Science·V PatelA Mann
May 16, 1998·Biological Psychiatry·S P MahadikJ S Mahadik
Jan 30, 1999·Psychoneuroendocrinology·C S Carter
Dec 26, 2001·Archives of General Psychiatry·S L BukaR H Yolken
Feb 4, 2003·The American Journal of Psychiatry·Martina C M RyanJogin H Thakore
Feb 18, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·O M WolkowitzV I Reus
Feb 25, 2003·International Clinical Psychopharmacology·Reiji YoshimuraJun Nakamura
Apr 2, 2003·The American Journal of Psychiatry·Gavin P ReynoldsXiaoBin Zhang
May 6, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Gil ZalsmanAbraham Weizman
Jul 3, 2003·Schizophrenia Research·Ravinder ReddyJeffrey K Yao
Mar 3, 2004·European Archives of Psychiatry and Clinical Neuroscience·F Markus LewekeRobert H Yolken
Apr 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·F M M A van der HeijdenW M A Verhoeven
Jun 29, 2004·Psychoneuroendocrinology·Martina C M RyanJogin H Thakore
Aug 4, 2004·Archives of General Psychiatry·Alan S BrownEzra S Susser
Feb 8, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Gavin P ReynoldsZhiJun Zhang
Apr 1, 2005·The American Journal of Psychiatry·Alan S BrownEzra S Susser
Jan 9, 2007·Biological Psychiatry·G Paul AmmingerRobert H Yolken
Mar 3, 2007·Schizophrenia Bulletin·Preben Bo MortensenRobert H Yolken
Apr 27, 2007·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·A PetersH L Fehm
Dec 29, 2007·The Journal of Clinical Psychiatry·Gregor E BergerPatrick D McGorry
Jul 29, 2008·Progress in Brain Research·Markus Heinrichs, Gregor Domes
Sep 18, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tzu-Hua WuMong-Liang Lu
Apr 9, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rael D StrousBaruch Spivak

❮ Previous
Next ❯

Citations

Dec 18, 2015·Journal of Affective Disorders·G FondUNKNOWN FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group
May 5, 2016·Schizophrenia Bulletin·Ewa BulzackaUNKNOWN FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
Jun 29, 2016·European Archives of Psychiatry and Clinical Neuroscience·G FondUNKNOWN FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Group
Mar 31, 2017·International Journal of Molecular Sciences·Matea Nikolac PerkovicNela Pivac
Dec 12, 2017·The International Journal of Neuropsychopharmacology·Maria Fe BarconesJuan Carlos Leza
Nov 12, 2017·European Archives of Psychiatry and Clinical Neuroscience·G FondUNKNOWN FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group
Feb 24, 2018·Schizophrenia Bulletin·Thomas A PollakPhilip McGuire
Mar 2, 2018·Journal of Neuroinflammation·María Juncal-RuizBenedicto Crespo-Facorro
Jan 19, 2019·Translational Psychiatry·Emanuela MartinuzziUNKNOWN OPTiMiSE Study Group
Aug 24, 2019·Molecular Psychiatry·Julia J WooJames L Kennedy
Nov 7, 2019·Journal of Clinical Psychopharmacology·Jie Yin YeeJimmy Lee
Mar 22, 2016·Current Opinion in Psychiatry·Lynn E DeLisi, W Wolfgang Fleischhacker
Feb 16, 2018·Cognitive Neuropsychiatry·Evangelos NtourosVasilios P Bozikas
May 11, 2019·European Psychiatry : the Journal of the Association of European Psychiatrists·Carlos González-VivasJulio Sanjuan
Mar 12, 2020·Neuropsychiatric Disease and Treatment·Gabriela RaduLiana Dehelean
Feb 27, 2017·European Archives of Psychiatry and Clinical Neuroscience·G FondUNKNOWN FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group
Nov 14, 2018·Translational Psychiatry·Anya SavranskyL Elliot Hong
Mar 9, 2019·Frontiers in Psychology·Hongyan Chen, Dingliang Tan
May 10, 2019·BJPsych Open·Stephen M LawrieAndrew M McIntosh
Jan 8, 2020·International Journal of Environmental Research and Public Health·Lampros Samartzis, Michael A Talias
Jun 1, 2017·NPJ Schizophrenia·Peter F Buckley, Brian J Miller
Jan 25, 2018·European Archives of Psychiatry and Clinical Neuroscience·C Arango
May 29, 2018·European Archives of Psychiatry and Clinical Neuroscience·G FondUNKNOWN FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
Aug 30, 2019·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Huajie JinJames H MacCabe
Sep 23, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mattia VeroneseOliver Howes
Sep 8, 2018·Frontiers in Psychiatry·Guillaume FondLaurent Boyer
Nov 30, 2018·Frontiers in Psychiatry·Jaana SuvisaariTuukka T Raij
Jun 5, 2017·Journal of Psychiatric Research·Daniela Rodrigues-AmorimRoberto C Agís-Balboa
Mar 17, 2020·Progress in Neuro-psychopharmacology & Biological Psychiatry·G FondUNKNOWN FACE-SZ group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here